Abstract
Aim: This study assessed the efficacy of anti-PD-1/PD-L1 agents in real life when used in second line or beyond. Materials & methods: Patients with advanced non-small-cell lung cancer progressing after standard chemotherapy and receiving immunotherapy in the second line or beyond were included. Results: One hundred and ten patients were included with PD-L1 expression above 50%, between 1–49 and <1% in 38.6, 27.3 and 34.1% of patients, respectively. Checkpoint inhibitors were used as second, third and fourth line in 74.7, 21.8 and 3.5%, respectively. Partial response was observed in 25.6% of patients. Median progression-free survival was 4 months and median overall survival was 8.1 months. Conclusion: Immunotherapies are emerging as important tools in the oncologic field with good responses in real-life practice.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung. Radiol. Oncol. 51(3), 357–362 (2017). • Shows the difference in PD-L1 expression between the different lung cancer subtypes, which could lead to different therapeutic strategies.
- 2. . Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur. J. Cancer 50, 1361–1369 (2014).
- 3. . Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Eur. J. Cancer 57, 91–103 (2016).
- 4. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann. Oncol. 27, 147–153 (2016). •• Highlights the heterogeneous state of PD-L1 expression, and the importance of large tumor sampling to adequately assess PD-L1.
- 5. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
- 6. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur. J. Cancer 101, 160e164 (2018).
- 7. . Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann. Oncol. 27, 1492e504 (2016).
- 8. . Hallmarks of response to immune checkpoint blockade. Br. J. Cancer 117, 1e7 (2017).
- 9. National Institute for Health and Care Excellence. Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (2017). www.nice.org.uk/guidance/ta428/resources/pembrolizumab-for-treating-pdl1positive-nonsmallcell-lung-cancer-after-chemotherapy-pdf-82604670410437
- 10. Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann. Oncol. 28, (Suppl. 5) mdx380.002 (2017). •• Overview of the duration of immunotherapy treatment, which is still a matter of debate.
- 11. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139e48 (2016).
